# Integrative Analysis of Pharmacogenomic Response in Cancer Cell Lines

**Authors:** G. Pharmacologist, H. Computational Biologist

**DOI:** 10.1234/bench.005

---

## Abstract

**Background:** Understanding drug-specific transcriptomic responses is essential for precision oncology. This study profiled 30 genes across 12 cancer cell line samples treated with two investigational compounds (Drug A and Drug B) compared to DMSO control.

**Methods:** RNA-seq count data for 30 genes were profiled across 12 samples (3 treatment groups × 4 biological replicates). Differential expression analysis was performed using DESeq2 v1.34.0 in R v4.1.0 on a Linux x86_64 platform. Comparisons were made for Drug A vs DMSO and Drug B vs DMSO. Visualization includes volcano plots and PCA.

**Results:** Drug A induced strong upregulation of *ERBB2*, *EGFR*, *MYC*, and *JUN*, and downregulation of *BCL2*, *MCL1*, and *BAX*. Drug B showed a distinct profile with upregulation of *BRAF*, *CDKN1A*, and *CASP3*, and downregulation of *MTOR*. PCA revealed clear separation of treatment groups from DMSO control.

**Conclusions:** Drug A and Drug B exhibit distinct transcriptomic signatures in cancer cell lines, suggesting different mechanisms of action. Drug A primarily targets proliferation and survival pathways, while Drug B induces cell cycle arrest and apoptosis.

---

## Introduction

Pharmacogenomic profiling enables systematic characterization of drug-induced transcriptomic changes. Comparing transcriptional responses across multiple compounds reveals both shared and drug-specific pathway perturbations. This study examines the transcriptomic response of a 30-gene panel — including oncogenes, tumor suppressors, apoptotic regulators, and cell cycle genes — to two investigational compounds.

We employ DESeq2 for differential expression analysis, followed by PCA for sample-level visualization. The analysis was performed on a Linux x86_64 platform with R 4.1.0 and Bioconductor 3.14.

---

## Methods

### Sample Preparation

RNA-seq was performed on 12 cancer cell line samples:
- **DMSO control:** 4 biological replicates (DMSO_1–4)
- **Drug A treatment:** 4 biological replicates (DrugA_1–4)
- **Drug B treatment:** 4 biological replicates (DrugB_1–4)

Each sample was profiled for the same 30 genes. The count matrix is provided as `counts.csv` (Supplementary Table S1).

### Differential Expression Analysis

Count data were normalized and analyzed using DESeq2 v1.34.0 in R v4.1.0. The analysis followed the standard DESeq2 workflow:

1. Load count matrix from CSV
2. Create DESeqDataSet with design formula `~ condition`
3. Run DESeq2 with default parameters
4. Apply log2 fold change shrinkage
5. Extract results at adjusted p-value < 0.05

```r
# Analysis code
dds <- DESeqDataSetFromMatrix(countData = counts, colData = coldata, design = ~ treatment)
dds <- DESeq(dds)
res <- results(dds, contrast = c("treatment", "DrugA", "DMSO"))
```

### Visualization

**Figure 1:** Volcano plot showing -log10(adjusted p-value) vs log2 fold change for Drug A vs DMSO. Genes with mean normalized count < 10 across all samples were excluded prior to differential expression analysis.

**Figure 2:** PCA plot of variance-stabilized transformed counts for all 12 samples, colored by treatment group.

### Software Versions

| Software | Version | Purpose |
|----------|---------|---------|
| R | 4.1.0 | Statistical computing environment |
| DESeq2 | 1.34.0 | Differential expression analysis |
| ggplot2 | — | Data visualization |
| Operating System | Ubuntu 20.04 LTS (x86_64) | Analysis platform |

---

## Results

### Drug A vs DMSO

Drug A treatment induced significant transcriptomic changes. *ERBB2* (log2FC = 2.8, padj = 0.0001), *EGFR* (log2FC = 2.1, padj = 0.0005), *MYC* (log2FC = 2.7, padj = 0.0001), and *JUN* (log2FC = 3.0, padj = 0.0001) were strongly upregulated. *BCL2* (log2FC = -2.5, padj = 0.0002), *MCL1* (log2FC = -2.8, padj = 0.0001), and *BAX* (log2FC = -1.5, padj = 0.001) were significantly downregulated.

### Drug B vs DMSO

Drug B showed a distinct expression profile. *BRAF* (log2FC = 2.2, padj = 0.0005), *CDKN1A* (log2FC = 2.5, padj = 0.0002), and *CASP3* (log2FC = 2.0, padj = 0.001) were upregulated. *MTOR* (log2FC = -1.8, padj = 0.0005) was downregulated.

### Table 1: Key Differentially Expressed Genes

| Gene | DrugA log2FC | DrugA padj | DrugB log2FC | DrugB padj |
|------|-------------|------------|-------------|------------|
| ERBB2 | 2.8 | 0.0001 | 1.0 | 0.05 |
| EGFR | 2.1 | 0.0005 | 0.5 | 0.20 |
| MYC | 2.7 | 0.0001 | 1.5 | 0.01 |
| JUN | 3.0 | 0.0001 | 1.8 | 0.005 |
| BCL2 | -2.5 | 0.0002 | 1.2 | 0.03 |
| MCL1 | -2.8 | 0.0001 | 0.8 | 0.10 |
| BRAF | -0.5 | 0.30 | 2.2 | 0.0005 |
| CDKN1A | 0.2 | 0.60 | 2.5 | 0.0002 |
| CASP3 | -0.8 | 0.10 | 2.0 | 0.001 |

*Significance threshold: q-value < 0.05 (Benjamini-Hochberg adjusted)*

---

### Figure 1: Volcano Plot — Drug A vs DMSO

![Figure 1: Volcano plot showing -log10(adjusted p-value) vs log2 fold change for Drug A vs DMSO. Upregulated genes (ERBB2, EGFR, MYC, JUN) appear in the upper-right quadrant. Downregulated genes (BCL2, MCL1, BAX) appear in the upper-left quadrant.](figures/figure1_volcano.png)

### Figure 2: PCA of Drug Treatment Samples

![Figure 2: PCA plot of variance-stabilized transformed counts, showing clear separation of Drug A, Drug B, and DMSO treatment groups.](figures/figure2_pca.png)

---

## Data Availability

The count matrix is available as Supplementary Table S1 (`counts.csv`), containing 30 rows (genes) and 12 columns (samples). The dataset is deposited at GEO under accession **GSE77777**. The analysis script is available at `https://github.com/example/pharmacogenomic-response`.

---

## Supplementary Materials

- **Supplementary Table S1:** Count matrix (30 genes × 12 samples)
- **Supplementary Table S2:** Complete differential expression results for all contrasts
- **Analysis Script:** R analysis script (`analysis.R`)